Teva reported today that the CoGenesys acquisition closed (#msg-26992602), and evidently there was no valuation adjustment. I would consider this bullish for Albuferon.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”